Yarvitan

RSS

mitratapide

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for this product has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 23/08/2011

Authorisation details

Product details
Name
Yarvitan
Agency product number
EMEA/V/C/000113
Active substance
mitratapide
International non-proprietary name (INN) or common name
mitratapide
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QA08AB90
Publication details
Marketing-authorisation holder
Janssen Pharmaceutica N.V.
Revision
3
Date of issue of marketing authorisation valid throughout the European Union
14/11/2006
Contact address
Turnhoutseweg 30
B-2340 Beerse
Belgium

Product information

20/10/2008 Yarvitan - EMEA/V/C/000113 - II/0003

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antiobesity preparations, excl. diet products

Therapeutic indication

As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight management programme which also includes appropriate dietary changes. Introducing appropriate lifestyle changes (e.g. increased exercise), in conjunction with this weight management programme, may provide additional benefits.

Assessment history

How useful was this page?

Add your rating
Average
1 rating